Paper33482121
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
Gay CM and 29 others. Cancer Cell, 2021. Cited by 863 papers, by iCite.
Cite this record
ConductScience Library. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Papers, record 33482121. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33482121
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
- PubMed
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunity | Major topic |
| Lung Neoplasms | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Transcription Factors | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Cisplatin | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Mice, Nude | |
| Prognosis | |
| Mice |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| U24 CA213274 | NCI NIH HHS | United States | U24CA213274 | PubMed and NIH | NIH RePORTER |
| R50 CA243698 | NCI NIH HHS | United States | R50CA243698 | PubMed and NIH | NIH RePORTER |
| R01 CA207295 | NCI NIH HHS | United States | R01CA207295 | PubMed and NIH | NIH RePORTER |
| P50 CA070907 | NCI NIH HHS | United States | P50CA070907 | PubMed and NIH | NIH RePORTER |
| T32 CA009666 | NCI NIH HHS | United States | T32CA009666 | PubMed and NIH | NIH RePORTER |
| U01 CA215845 | NCI NIH HHS | United States | U01CA215845 | PubMed | NIH RePORTER |
| U01 CA213273 | NCI NIH HHS | United States | U01CA213273 | PubMed and NIH | NIH RePORTER |
| P30 CA034196 | NCI NIH HHS | United States | P30CA034196 | PubMed and NIH | NIH RePORTER |
| U01 CA213338 | NCI NIH HHS | United States | U01CA213338 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05257551 | Tempus Small Cell Lung Cancer Observational Study (Sculptor) | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 33577787 | Small cell lung cancer enters the era of precision medicine. | https://conductscience.org/library/papers/33577787 |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31061481 | Determining cell type abundance and expression from bulk tissues with digital cytometry. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/31061481 | PubMed |
| 2 | 29118061 | Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29118061 | PubMed |
| 3 | 28844817 | Labetuzumab govitecan in metastatic colorectal cancer. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28844817 | PubMed |
| 4 | 30926931 | Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/30926931 | PubMed |
| 5 | 31870883 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. | J Thorac Oncol | 2020 | https://conductscience.org/library/papers/31870883 | PubMed |
| 6 | 31416802 | Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31416802 | PubMed |
| 7 | 28212573 | Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28212573 | PubMed |
| 8 | 26168399 | Comprehensive genomic profiles of small cell lung cancer. | Nature | 2015 | https://conductscience.org/library/papers/26168399 | PubMed |
| 9 | 30280641 | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30280641 | PubMed |
| 10 | 29088717 | Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. | Oncotarget | 2017 | https://conductscience.org/library/papers/29088717 | PubMed |
| 11 | 27269741 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27269741 | PubMed |
| 12 | 22961666 | Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Cancer Discov | 2012 | https://conductscience.org/library/papers/22961666 | PubMed |
| 13 | 30089906 | RNA velocity of single cells. | Nature | 2018 | https://conductscience.org/library/papers/30089906 | PubMed |
| 14 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 15 | 30038220 | Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. | Nat Med | 2018 | https://conductscience.org/library/papers/30038220 | PubMed |
| 16 | 30557521 | T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30557521 | PubMed |
| 17 | 30257981 | Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30257981 | PubMed |
| 18 | 27452466 | ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. | Cell Rep | 2016 | https://conductscience.org/library/papers/27452466 | PubMed |
| 19 | 28089889 | MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. | Cancer Cell | 2017 | https://conductscience.org/library/papers/28089889 | PubMed |
| 20 | 30231367 | Immune Checkpoint Inhibitors in the Management of Lung Cancer. | Am Soc Clin Oncol Educ Book | 2018 | https://conductscience.org/library/papers/30231367 | PubMed |
Cited by635
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 863 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42989294 | MAP of molecular analyses in real-worlD oncology centers - MAPpaMoNDO: a study of the translational research Young GOIM group. | J Transl Med | 2026 | https://conductscience.org/library/papers/42989294 | PubMed |
| 42983745 | SCG3 and YAP1 define molecular subtypes of small cell carcinoma of the cervix with divergent multi-omics features and prognostic outcomes. | J Transl Med | 2026 | https://conductscience.org/library/papers/42983745 | PubMed |
| 42974076 | Development and Validation of a Gene Expression-Based Prognostic Model for Patients With Small Cell Lung Cancer Treated With Chemotherapy. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42974076 | PubMed |
| 42967940 | Molecular and immune heterogeneity across limited-stage and extensive-stage small cell lung cancer. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42967940 | PubMed |
| 42914976 | Cell-state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer. | Cell | 2026 | https://conductscience.org/library/papers/42914976 | PubMed |
| 42907953 | Clinical and pathological characteristics, immune microenvironment, and survival analysis of molecular subtypes of surgically resected small cell lung cancer. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42907953 | PubMed |
| 42905834 | CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. | Sci Adv | 2026 | https://conductscience.org/library/papers/42905834 | PubMed |
| 42903730 | Spatial and maturational characterisation of tertiary lymphoid structures predicts immunotherapy response in extensive-stage small cell lung cancer. | Clin Transl Immunology | 2026 | https://conductscience.org/library/papers/42903730 | PubMed |
| 42900351 | Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer. | Target Oncol | 2026 | https://conductscience.org/library/papers/42900351 | PubMed |
| 42894882 | NK cell immune fitness stratifies small cell lung cancer into four functional states associated with clinical response. | J Liq Biopsy | 2026 | https://conductscience.org/library/papers/42894882 | PubMed |
| 42882853 | AI-Driven Multi-Omics Approaches for Deciphering Small-Cell Lung Cancer Heterogeneity Using Nucleic-Acid-Based Features. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882853 | PubMed |
| 42876375 | Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/42876375 | PubMed |
| 42875653 | Reframing cancer therapy through tumor plasticity. | Nat Cancer | 2026 | https://conductscience.org/library/papers/42875653 | PubMed |
| 42866165 | Artificial intelligence and radiomics in small cell lung cancer: a narrative review of imaging and multisource data integration. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/42866165 | PubMed |
| 42840183 | The Five-Decade Journey of Small Cell Lung Cancer. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42840183 | PubMed |
| 42820295 | Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42820295 | PubMed |
| 42814835 | Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. | Sci Adv | 2026 | https://conductscience.org/library/papers/42814835 | PubMed |
| 42778205 | Thymic neuroendocrine tumours: molecular landscape, immune microenvironment and therapeutic perspectives. | Eur Respir Rev | 2026 | https://conductscience.org/library/papers/42778205 | PubMed |
| 42768009 | XPO1-mediated TRIM21 nuclear export reprograms TREM2+ macrophage polarization by targeting IRF3 to augment anti-PD-1 efficacy in small cell lung cancer. | Nat Commun | 2026 | https://conductscience.org/library/papers/42768009 | PubMed |
| 42761714 | Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection. | Front Immunol | 2026 | https://conductscience.org/library/papers/42761714 | PubMed |
Genes53
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33482121
GET https://conductscience.org/api/papers/v1/33482121/authors?page=2